MedPath

Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma

Not Applicable
Completed
Conditions
Atopic Asthma
Interventions
Drug: Placebo
Registration Number
NCT02327234
Lead Sponsor
University of Saskatchewan
Brief Summary

The study will assess airway responses in mild atopic asthmatics undergoing repeat allergen challenge testing and will investigate whether ibuprofen changes the response.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
13
Inclusion Criteria
  • diagnosis of mild asthma, currently well controlled requiring only a bronchodilator (e.g. salbutamol) as needed and infrequently
  • has allergies that trigger asthma
  • responds to methacholine challenge at 16mg/ml or less
  • has FEV1 > 69.5% predicted
Exclusion Criteria
  • respiratory illness within 4 weeks
  • other medical condition assessed by the principal investigator that would put the participant at risk or influence the integrity of the data
  • pregnant or lactating females
  • hypersensitivity to ibuprofen

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Ibuprofenibuprofen400mg (2X200mg) ibuprofen single dose once
PlaceboPlaceboidentical appearing lactose capsules single dose 2 capsules once
Primary Outcome Measures
NameTimeMethod
Airway response to inhaled allergenat time of allergen inhalation challenge and for 7 hours after

area under forced expiratory volume in one second versus time curve; 0-3hours (early response) and 3-7 hours (late response)

Secondary Outcome Measures
NameTimeMethod
Airway response to inhaled methacholineday before allergen inhalation challenge and 8 hours after allergen inhalation challenge

delta log methacholine PC20 (provocative concentration of methacholine causing a 20% decrease in the forced expiratory volume in one second)

Trial Locations

Locations (1)

University of Saskatchewan

🇨🇦

Saskatoon, Saskatchewan, Canada

© Copyright 2025. All Rights Reserved by MedPath